CLINAM European Foundation for Clinical Nanomedicine I2/2020Basel, October 25–28
Total Page:16
File Type:pdf, Size:1020Kb
CLINAM European Foundation for Clinical Nanomedicine I2/2020Basel, October 25–28 CURRICULA VITAE SPEAKERS • Rocas P, Fernández Y, García-Aranda N, Foradada L, Calvo P, Avilés P, Guillén MJ, Schwartz S Jr, Rocas J, Albericio F, Abasolo Ibane Abasolo I. Improved pharmacokinetic profile of lipophilic anti-cancer Dr. Abasolo is coordinator of the Function- drugs using ανβ3-targeted polyurethane-polyurea nanopar- al Validation & Preclinical Research (FVPR) ticles. Nanomedicine. 2018 Feb;14(2):257-267. doi: 10.1016/j. area of the CIBBIM-Nanomedicine, at the nano.2017.10.009. Epub 2017 Nov 7. PubMed PMID: 29127040. Vall d’Hebron Research Institute (VHIR, • Giannotti MI, Abasolo I, Oliva M, Andrade F, García-Aranda N, Barcelona). As head of FVPR, Dr. Abasolo Melgarejo M, Pulido D, Corchero JL, Fernández Y, Villaverde A, is responsible for standardizing trials with Royo M, García-Parajo MF, Sanz F, Schwartz S Jr. Highly Versatile which to test therapeutic agents, nanosys- Polyelectrolyte Complexes for Improving the Enzyme Replace- tems or candidate genes, offering industry ment Therapy of Lysosomal Storage Disorders. ACS Appl Mater and other research groups a technologi- Interfaces. 2016 Oct 5;8(39):25741-25752. Epub 2016 Sep 22. cal platform with which to advance the preclinical development PubMed PMID: 27610822. of their compounds. In fact, FVPR is part of unit 20 (Experimenta- tionin vivo) of the platforms of the CIBER-BBN (Spanish Network in Bio-enginery, Biomaterials and Nanomedicine) and of the Singular Technical Scientific Infrastructure (ICTS) Nanbiosis. Ibane Abasolo obtained the Bachelor’s degrees in Biochemistry Karin Abitorabi and Biology from the University of Navarra in 1997 and 1998, re- spectively. During her doctorate in the laboratories of Dr. Alfonso Karin Abitorabi obtained her Diplom in Im- Calvo (CIMA, Pamplona) and Prof. Zhou Wang (Northwestern Uni- munology and Microbiology from the Uni- versity, Chicago, USA), he studied the role of a peptide hormone, versity of Konstanz, Germany. adrenomedullin, in prostate cancer. Later, Dr. Abasolo continued Karin has had a very distinguished and her post-doctoral training in the group of Prof. F.X. Real (IMIM, successful career with over 20 years of Barcelona), where he focused on the study of key molecules in experience from discovery research to de- the progression of pancreatic cancer and cerebellar development. velopment of therapeutic drugs and is an During this time, Dr. Abasolo gained experience in experimental internationally recognized expert in cell mouse models, from the generation of transgenic models to the therapy development. molecular and cellular characterization of pre-existing models. In Prior to joining Novartis, she worked independently as a consultant 2016, Dr. Abasolo moved to Insitut d’Alta Tecnologia (PRBB, Bar- at Cell Therapy and Flow Cytometry and worked on various clinical celona), where she trained in molecular imaging techniques such studies, at PCT (Progenitor Cell Therapy) leading Process Develop- as microPET, SPECT and CT. In 2017, she joined the lab of Dr. Simó ment in Mountain View, California, in the departments of Hemato- Schwartz at the CIBBIM-Nanomedicine center at VHIR and since poietic Transplantation at SyStemix, Inc., Preclinical Oncology and then she has been working on the preclinical validation in( vitro and Immunology at Cell Genesys Inc., and Research at Schering-Plough in vivo) of different type of nanomaterials. She has been focusing in BioPharma (formerly DNAX, now Merck Research Labs). She has two main indications, drug-resistant and difficult-to-treat cancers worked as a key team member on separate therapeutic programs and of lysosomal storage disorders, currently lack a definitive cura- leading to IND filings. tive treatment. In 2013 Karin joined the Cell and Gene Therapy department at Currently Dr. Abasolo leads 2 European research projects (Di- Novartis in Basel and significantly contributed to the success of a amESTar and Smart4Fabry) and participates directly in the Euro- variety of pipeline programs including the Kymriah program. Karin pean projects NoCanTher, Evo-Nano and Safe-Med-Tech led by Dr. collaborated with a network of international CMOs and effectively Schwartz (CIBBIM-Nanomedicine, VHIR). Importantly, Dr. Abasolo facilitated the transfer of Novartis process technology. She was is the PI of a national grant (PI18/00871, by ISCiii) focused on im- also instrumental in process improvements and for the progression proving the treatment of lysosomal storage disorders using differ- of several hematopoietic stem cell program efforts into the clinic. ent nanometric systems, extracellular vesicles, among them. Re- search career of Dr. Abasolo is supported by her publications in the field of cancer, lysosomal diseases and nanotechnology, as well as her extensive network of collaborators nationally and internation- ally. Gabriel Aeppli RECENT PUBLICATIONS • Pesarrodona M, Jauset T, Díaz-Riascos ZV, Sánchez-Chardi A, Gabriel Aeppli is professor of physics at Beaulieu ME, Seras-Franzoso J, Sánchez-García L, Baltà-Foix R, ETH Zürich and EPF Lausanne, and head of Mancilla S, Fernández Y, Rinas U, Schwartz S Jr, Soucek L, Vil- the Synchrotron and Nanotechnology divi- laverde A, Abasolo I, Vázquez E. Targeting Antitumoral Proteins sion of the Paul Scherrer Institute. All of his to Breast Cancer by Local Administration of Functional Inclusion degrees are from MIT and include a BSc in Bodies. Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/ Mathematics and Electrical Engineering, advs.201900849. eCollection 2019 Sep 18. PubMed PMID: and MSc and PhD in Electrical Engineer- 31559131; PubMed Central PMCID: PMC6755514. ing. A large fraction of his career was in • Rafael D, Gener P, Andrade F, Seras-Franzoso J, Montero S, industry, where, starting as a work-study Fernández Y, Hidalgo M, Arango D, Sayós J, Florindo HF, Aba- student at IBM and after his PhD moving to Bell Laboratories and solo I, Schwartz S Jr, Videira M. AKT2 siRNA delivery with then NEC, he worked on problems ranging from liquid crystals to amphiphilic-based polymeric micelles show efficacy against magnetic data storage. He was subsequently co-founder and direc- cancer stem cells. Drug Deliv. 2018 Nov;25(1):961-972. doi: tor of the London Centre for Nanotechnology and Quain Professor 10.1080/10717544.2018.1461276. PubMed PMID: 29667444; at University College London. Aeppli also cofounded the Bio-Nano PubMed Central PMCID: PMC6060707. Consulting Company, of which he remains a non-executive director. • Cacicedo ML, Islan GA, León IE, Álvarez VA, Chourpa I, Allard-Van- He is a frequent advisor to numerous private and public entities nier E, García-Aranda N, Díaz-Riascos ZV, Fernández Y, Schwartz worldwide (including China, Australia, Europe and the US) engaged S Jr, Abasolo I, Castro GR. Bacterial cellulose hydrogel loaded in the funding, evaluation and management of science and tech- with lipid nanoparticles for localized cancer treatment. Colloids nology. Honors include the Mott Prize of the Institute of Physics Surf B Biointerfaces. 2018 Oct 1;170:596-608. doi: 10.1016/j.col- (London), the Oliver Buckley prize of the American Physical Society, surfb.2018.06.056. Epub 2018 Jun 26. PubMed PMID: 29975908. the Néel Medal/International Magnetism Prize of the International 2 Union of Pure and Applied Physics, and election to the American • Johnson MB, Halman JR, Satterwhite E, Zakharov AV, Bui MN, Academy of Arts and Sciences and the Royal Society (London). Benkato K, Goldsworthy V, Kim TJ, Hong E, Dobrovolskaia MA, Kh- Aeppli’s scientific research is currently focused on the applica- isamutdinov E, Marriott I, Afonin KA. Programmable nucleic acid- tions of nanotechnology and photon science to biomedicine and based polygons with controlled neuroimmunomodulatory prop- quantum information processing. Projects include the develop- erties for predictive QSAR modeling. Small, 13(42), 2017. PMID: ment of optical and microwave tools for medical diagnostics and 28922553 pharmacology, where we are interested in new drug-target and antibody-antigen binding assays. We pay particular attention to obtaining specific, quantitative results, as well as to ease of use and (eventual) low cost for our engineered systems. Photons are also at the heart of efforts to control and read out quantum states Maria Pilar in solids, including especially silicon, for which we exploit coher- Aguar-Fernandez ent, tunable pulses of THz radiation from a free electron laser. Our most recent work (2015) describes the electrical detection of co- Head of Unit Health innovations herent orbital superpositions in a commercial silicon wafer. A re- DG RTD lated topic is adiabatic quantum computing, where calculations are Ms. Aguar joined the EC working for the performed by mapping problems onto networks of bits, and then DG for Health & Consumers on evaluation relaxing the networks via quantum mechanics. This procedure is of the performance of national authorities most easily modeled in the limits of very large networks using mag- and food-safety control systems in 2001. nets (although programmable medium size networks containing of From 2005 to 2012, she was involved in de- order 1000 bits are now being implemented using superconducting velopment and management of European junctions), where the bits correspond to Ising spins with either up Research Programmes in DG Research & Innovation in the area of or down magnetization, and quantum mechanics is introduced via Industrial Technologies. a “transverse”